Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study

Diabetes, Obesity and Metabolism

Volumn 15, Issue 3, 2013, Pages 204-212

  Nauck, M ^a   Frid, A ^b   Hermansen, K ^c   Thomsen, A B ^d   During, M ^d   Shah, N ^e   Tankova, T ^f   Mitha, I ^g   Matthews, D R ^h  

^a DIABETESZENTRUM BAD LAUTERBERG   (Germany)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c AARHUS UNIVERSITY HOSPITAL   (Denmark)

^d Novo Nordisk Pharma GmbH   (Germany)

^e KEM HOSPITAL   (India)

^f MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^g Benmed Hospital   (South Africa)

^h UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

GLP 1 analogue; Type 2 diabetes

Indexed keywords

GLIMEPIRIDE; GLUCAGON; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIRAGLUTIDE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO;

ADULT; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BACKACHE; BODY MASS; BRONCHITIS; CARDIOVASCULAR RISK; CONTROLLED STUDY; COUGHING; DECREASED APPETITE; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; EYE DISEASE; GASTRITIS; GLUCAGON BLOOD LEVEL; GLYCEMIC CONTROL; HEADACHE; HEART DISEASE; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; HYPOGLYCEMIA; INFLUENZA; INSULIN RESISTANCE; KIDNEY DISEASE; LONG TERM CARE; MAJOR CLINICAL STUDY; MENTAL DISEASE; MONOTHERAPY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PANCREAS ISLET ALPHA CELL; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PULSE RATE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; RISK; SKIN DISEASE; SYSTOLIC BLOOD PRESSURE; TOOTH PAIN; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VOMITING; WEIGHT GAIN; WEIGHT REDUCTION;

EID: 84873085581     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12012     Document Type: Article

References (14)

1. Inzucchi SE, Bergenstal RM, Buse RM et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia 2012; 55: 1577-1596.
2. Rodbard HW, Jellinger PS, Davidson JA et al. Statement by an American Association of Clinical Endocrinologists/American College of Endocrinology consensus panel on type 2 diabetes mellitus: an algorithm for glycemic control. Endocr Pract 2009; 15: 540-559.
3. National Institute for Health and Clinical Excellence. Type 2 diabetes: newer agents for blood glucose control in type 2 diabetes. Available from URL: http://www.nice.org.uk/nicemedia/live/12165/44318/44318.pdf. Accessed 28 June 2012.
4. Marre M, Shaw J, Brändle M et al. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in patients with type 2 diabetes (LEAD-1 SU). Diabet Med 2009; 26: 268-278.
5. Nauck M, Frid A, Hermansen K et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care 2009; 32: 84-90.
6. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
7. Zinman B, Gerich J, Buse JB et al. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). Diabetes Care 2009; 32: 1224-1230.
8. Russell-Jones D, Vaag A, Schmitz O et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009; 52: 2046-2055.
9. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomized parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
10. Pratley R, Nauck M, Bailey T et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010; 375: 1447-1456.
11. Buse JB, Sesti G, Schmidt WE et al. Switching to once-daily liraglutide from twice-daily exenatide further improves glycemic control in patients with type 2 diabetes using oral agents. Diabetes Care 2010; 33: 1300-1303.
12. Pratley R, Nauck M, Bailey T et al. One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial. Int J Clin Pract 2011; 65: 397-407.
13. Day C, Bailey CJ. HBA1c - changing units. Br J Diabetes Vasc Dis 2009; 9: 134-136.
14. Garber A, Henry RR, Ratner R, Hale P, Chang CT, Bode B. Liraglutide, a once-daily human GLP-1 analogue, provides sustained improvements in glycaemic control and weight for two years as monotherapy compared with glimepiride in patients with type 2 diabetes. Diabetes Obes Metab 2011; 13: 348-356.